{"id":966145,"date":"2026-05-21T17:21:01","date_gmt":"2026-05-21T21:21:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"modified":"2026-05-21T17:21:01","modified_gmt":"2026-05-21T21:21:01","slug":"enliven-therapeutics-to-present-at-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/","title":{"rendered":"Enliven Therapeutics to Present at Upcoming Investor Conferences"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n BOULDER, Colo.<\/span>, May 21, 2026<\/span> \/PRNewswire\/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences:<\/p>\n

TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHA
Format: Fireside Chat
Date: Wednesday, May 27
Time: 2:30 p.m. ET<\/p>\n

Jefferies Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, June 4
Time: 11:40 a.m. ET<\/p>\n

The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https:\/\/ir.enliventherapeutics.com\/<\/a>. The webcast will be archived for a period of 90 days following the conclusion of the live event.<\/p>\n

\n About Enliven Therapeutics
<\/b>Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. To learn more, visit www.enliventherapeutics.com<\/a> and connect with us on LinkedIn<\/a> and X<\/a>.<\/p>\n

\n

\n
\n \"Enliven
\n <\/a>\n <\/p>\n<\/p><\/div>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-302779411.html<\/a><\/p>\n

SOURCE Enliven Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BOULDER, Colo., May 21, 2026 \/PRNewswire\/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 11:40 a.m. ET The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https:\/\/ir.enliventherapeutics.com\/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a … <\/p>\n

Continue reading “Enliven Therapeutics to Present at Upcoming Investor Conferences”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966145","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEnliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOULDER, Colo., May 21, 2026 \/PRNewswire\/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 11:40 a.m. ET The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https:\/\/ir.enliventherapeutics.com\/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a … Continue reading "Enliven Therapeutics to Present at Upcoming Investor Conferences"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T21:21:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enliven Therapeutics to Present at Upcoming Investor Conferences\",\"datePublished\":\"2026-05-21T21:21:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"},\"wordCount\":226,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\",\"name\":\"Enliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"datePublished\":\"2026-05-21T21:21:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2552156\\\/Enliven_Therapeutics___Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enliven Therapeutics to Present at Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Enliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire BOULDER, Colo., May 21, 2026 \/PRNewswire\/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following investor conferences: TD Cowen Annual Oncology Innovation Summit: Insights for ASCO & EHAFormat: Fireside ChatDate: Wednesday, May 27Time: 2:30 p.m. ET Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Thursday, June 4Time: 11:40 a.m. ET The fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at https:\/\/ir.enliventherapeutics.com\/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a … Continue reading \"Enliven Therapeutics to Present at Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T21:21:01+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enliven Therapeutics to Present at Upcoming Investor Conferences","datePublished":"2026-05-21T21:21:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/"},"wordCount":226,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/","name":"Enliven Therapeutics to Present at Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","datePublished":"2026-05-21T21:21:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2552156\/Enliven_Therapeutics___Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enliven-therapeutics-to-present-at-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enliven Therapeutics to Present at Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966145"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}